MS Treatment: What Brain and Spine Scans Can Reveal
By MS Buddy ·
Summarized from Journal of neurology, Oct 2026 · PubMed. AI-generated summary. Not medical advice.
Research by Bertrand Bourre, Jonathan Ciron and 7 colleagues at Department of Neurology and Inserm, Valence Hospital and 5 other institutions in France.
Key Takeaway
In a survey of French MS specialists, certain brain and spine scan findings strongly influenced whether they recommended starting a powerful MS treatment right away.
What They Found
Thirty-one French neurologists reviewed examples of people with relapsing-remitting MS who had not yet started treatment. This type of MS involves periods when symptoms get worse, followed by times of recovery. The specialists were asked whether they would recommend starting a high-efficacy treatment, a powerful medicine designed to reduce MS activity. They consistently recommended it when scans showed more than 20 brain lesions, at least two spinal cord lesions, at least three newly active lesions, or at least three lesions in the lower part of the brain. Lesions are areas of MS-related damage; one spinal cord lesion also led to a consistent recommendation when it appeared alongside other concerning findings.
Who Should Care and Why
People newly diagnosed with relapsing-remitting MS may find this study useful when discussing their first treatment. Brain and spine scans can show MS activity that is not obvious from symptoms alone, much like a weather map can show a storm before it reaches you. If your scan report mentions lesions, ask your MS specialist what their number and location mean for your treatment choices. Caregivers can help by writing down questions and taking notes during the visit. Doctors may use both scan results and a person's symptoms when talking through whether to start a powerful treatment early.
Important Considerations
This was a survey of 31 specialists in France, not a study testing which treatment worked best for patients. Their agreement does not mean the same choice is right for every person with MS. Ask your care team how these findings fit your full health picture before making a treatment decision.
AI-generated summary — for informational purposes only, not medical advice
Read the original abstract
Published in Journal of neurology by et al.. Reproduced from the PubMed record.
To gather expert consensus regarding initiation of monoclonal high-efficacy therapies (HET) amongst treatment-naïve relapsing-remitting multiple sclerosis (RRMS) patients in France. The study leveraged the Delphi method to gauge consensus amongst an expert panel of 31 neurologists. Eight clinical cases with demographic, clinical and imaging characteristics were presented, prompting the experts to respond if they would recommend monoclonal HET. Additionally, potentially influential parameters were changed one at a time to assess whether the experts would recommend monoclonal HET. After a first round, an e-workshop was conducted to discuss non-consensual statements, which were re-submitted for rating (Round 2). Characteristics influencing monoclonal HET initiation were evaluated. 31/31 experts responded to both rounds. Consensus for or against monoclonal HET was reached for 89/108 (82.4%) statements. Factors that systematically led to monoclonal HET initiation were high brain lesion load (>20 lesions), ≥2 spinal cord lesions, ≥3 gadolinium-enhancing lesions and ≥3 infratentorial lesions. A single spinal cord lesion, in combination with other factors (which, in isolation, often but not always led to monoclonal HET), systematically led to monoclonal HET recommendation. This study suggests that the panel of French neurologists favoured monoclonal HET initiation amongst treatment-naïve RRMS patients with high radiological disease activity, whereas clinical characteristics played a complementary role.
Explore more research
Check out the MS Buddy app
It’s free, with no ads. Built by people living with MS.
Related MS research
11/9/2026
A U.S. study found anxiety, depression, and pain more often in MS hospital stays. Learn why asking f
Read More
11/7/2026
A study of 360 people with MS links past suicide attempts with depression, smoking, and childhood ha
Read More
11/4/2026
A four-year MS study links the condition of nerve coating in brain lesions with later thinking speed
Read More
11/3/2026
A study of two MS medicines found MRI scans may help confirm relapses and clarify treatment differen
Read More
11/3/2026
A large MS records study found fewer Alzheimer’s diagnoses among people given natalizumab. Learn wha
Read More
11/3/2026
Sexual health concerns are common with MS. Learn how symptoms and pregnancy plans may affect intimac
Read MoreNot all studies carry the same weight: sample size, study design and whether results were replicated all matter. The credibility score above reflects the journal, and the original paper is linked under More Details. Read how MS Buddy selects and scores research, and talk to your MS care team before acting on any study.